- Home
- MESO vs BRCB Comparison
MESO vs BRCB Comparison
Compare MESO & BRCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MESO
- BRCB
- Stock Information
- Founded
- MESO 2004
- BRCB 2008
- Country
- MESO Australia
- BRCB United States
- Employees
- MESO N/A
- BRCB N/A
- Industry
- MESO Biotechnology: Biological Products (No Diagnostic Substances)
- BRCB
- Sector
- MESO Health Care
- BRCB
- Exchange
- MESO Nasdaq
- BRCB Nasdaq
- Market Cap
- MESO 1.3B
- BRCB 1.3B
- IPO Year
- MESO N/A
- BRCB 2025
- Fundamental
- Price
- MESO $18.18
- BRCB $23.58
- Analyst Decision
- MESO Buy
- BRCB Buy
- Analyst Count
- MESO 2
- BRCB 5
- Target Price
- MESO $24.00
- BRCB $28.50
- AVG Volume (30 Days)
- MESO 319.1K
- BRCB 554.4K
- Earning Date
- MESO 08-28-2025
- BRCB 11-06-2025
- Dividend Yield
- MESO N/A
- BRCB N/A
- EPS Growth
- MESO N/A
- BRCB N/A
- EPS
- MESO N/A
- BRCB N/A
- Revenue
- MESO $17,198,000.00
- BRCB $179,481,000.00
- Revenue This Year
- MESO $288.50
- BRCB N/A
- Revenue Next Year
- MESO $167.17
- BRCB N/A
- P/E Ratio
- MESO N/A
- BRCB N/A
- Revenue Growth
- MESO 191.39
- BRCB 20.84
- 52 Week Low
- MESO $7.09
- BRCB $20.39
- 52 Week High
- MESO $22.00
- BRCB $30.40
- Technical
- Relative Strength Index (RSI)
- MESO 58.45
- BRCB N/A
- Support Level
- MESO $17.10
- BRCB N/A
- Resistance Level
- MESO $20.18
- BRCB N/A
- Average True Range (ATR)
- MESO 0.56
- BRCB 0.00
- MACD
- MESO 0.17
- BRCB 0.00
- Stochastic Oscillator
- MESO 55.52
- BRCB 0.00
About MESO Mesoblast Limited
Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.